The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
|Brand Name||Generic name||Therapeutic Area||Recommendation Type||Project Status Sort descending||Date Submission Received||Date Recommendation Issued|
|Xofluza||baloxavir marboxil||Influenza||CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer|
|Imbruvica||ibrutinib||CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer|
|BuTrans||Buprenorphine transdermal patch||Pain, persistent (moderate intensity)||Cancelled||Oct 15, 2010|
|Pradaxa||Dabigatran etexilate||Atrial fibrillation prevention of stroke and systemic embolism||Cancelled||May 31, 2010|
|Brilinta||Ticagrelor||Acute Coronary Syndromes||Cancelled||Jun 8, 2010|